Sitryx announces partner Lilly exercises option to SIT-011 for chronic autoimmune and inflammatory diseases
01 nov. 2023 03h00 HE
|
Sitryx Therapeutics
Lilly exercises option to an exclusive worldwide license to develop and commercialize SIT-011, a Phase 1 ready immunometabolism-targeting therapy for chronic autoimmune and inflammatory...
World Leaders in Proteomics and Genomics to Convene at the 2nd International Top-Down Proteomics Symposium
20 sept. 2023 11h11 HE
|
Consortium for Top-Down Proteomics
Building the bridge from genotype to phenotype, the Symposium will feature scientific leaders creating cutting edge technologies and approaches that are ushering in the era of proteoform systems...
The Consortium for Top-Down Proteomics Announces the 2nd International Top-Down Proteomics Symposium, October 3-5, 2023, in Chicago, IL
01 mars 2023 10h17 HE
|
Consortium for Top-Down Proteomics
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- The Consortium for Top-Down Proteomics today announced the 2nd International Top-Down Proteomics Symposium, which will be held in Chicago, IL...
Lilly and ProQR to Expand RNA Editing Collaboration
22 déc. 2022 06h00 HE
|
ProQR Therapeutics N.V.
INDIANAPOLIS; LEIDEN, Netherlands; and CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Eli Lilly and Company (NYSE: LLY) and ProQR Therapeutics N.V. (Nasdaq: PRQR), today announced the expansion...
ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly
08 sept. 2021 16h01 HE
|
ProQR Therapeutics N.V.
Companies will collaborate to develop editing oligonucleotides directed to up to five targets using ProQR’s proprietary Axiomer® RNA editing platformProQR to receive $50 million consisting of upfront...
Sermonix Pharmaceuticals to Collaborate With Eli Lilly and Company in Studying Combination of Lasofoxifene and Lilly’s CDK 4 and 6 Inhibitor, Abemaciclib, in Metastatic Breast Cancer
08 juil. 2020 10h00 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, July 08, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
IBRI Drives New Collaboration Model Targeting Type 2 Diabetes
22 déc. 2016 11h45 HE
|
Indiana Biosciences Research Institute
INDIANAPOLIS, Ind., Dec. 22, 2016 (GLOBE NEWSWIRE) -- The Indiana Biosciences Research Institute (IBRI) today announced a new collaboration with Eli Lilly and Company, Roche Diagnostics, the...
Documents Uncovered by Judicial Watch Detail Big Pharma Campaign Access to Democratic Governors During 2012 National Governors Association Meeting
28 mars 2012 14h11 HE
|
Judicial Watch
WASHINGTON, DC--(Marketwire - Mar 28, 2012) - Judicial Watch, the public interest group that investigates and prosecutes government corruption, announced today that it has uncovered documents...